Table 5.
Preliminary baseline antibody data (based on a subset of samples of the PREVAC trial participants from version 2.0, 3.0 and 4.0 that were not randomly selected)
| PREVAC baseline antibody titers by age | ||||||
|---|---|---|---|---|---|---|
| Age | No. | GMT* EU/mL |
Median (IQR) EU/mL |
5th, 95th percentile | ≥ 200 EU/mL No. (%) |
> 607 EU/mL No. (%) |
| All children | 413 | 81.3 | 68 (47, 116) | 30, 451 | 54 (13.1%) | 15 (3.6%) |
| 1–4 years | 44 | 68.2 | 56 (43, 90) | 26, 227 | 4 (9.1%) | 2 (4.5%) |
| 5–11 years | 162 | 78.4 | 68 (46, 119) | 28, 351 | 21 (13.0%) | 4 (2.5%) |
| 12–17 years | 207 | 86.9 | 71 (49, 117) | 34, 470 | 29 (14.0%) | 9 (4.3%) |
| All adults | 677 | 83.7 | 74 (52, 114) | 34, 317 | 74 (10.9%) | 11 (1.6%) |
| 18–25 years | 392 | 86.0 | 75 (52, 122) | 33, 335 | 45 (11.5%) | 8 (2.0%) |
| 26–45 years | 205 | 78.7 | 69 (50, 103) | 35, 269 | 19 (9.3%) | 2 (1.0%) |
| 46+ years | 80 | 86.5 | 73 (54, 126) | 37, 300 | 10 (12.5%) | 1 (1.3%) |
| All ages | 1090 | 82.8 | 72 (50, 116) | 33, 330 | 128 (11.7%) | 26 (2.4%) |
*Geometric mean titer of antibody testing through 22 September 2019